中文摘要：

目的：评估 DC-CIK 细胞免疫治疗联合分子靶向药物治疗转移性胃肠恶性肿瘤的临床应用价值。方法随机将60例胃肠恶性肿瘤分为 DC-CIK、靶向加化疗组（联合组 A，20例）、靶向加化疗组（联合组 B，20例）和单纯化疗组（对照组，20例）。抽取患者静脉血50ml，行 DC-CIK 培养，14天后，对联合组 A 患者进行输注。观察治疗前后瘤体变化、体质量变化、K arnofsky 评分等。用 K arno fsky 评分及体质量的改变评价生存质量。结果对照组患者完全缓解（ CR ）2例,部分缓解（ PR ）3例,好转（ MR ）8例,稳定（ SD ）3例,无改变（ PD ）4例,总有效率（ CR ＋ PR ）为25.0%。联合组 B完全缓解（ CR ）3例,部分缓解（ PR ）7例,好转（M R ）7例,稳定（ SD ）2例,无改变（ PD ）1例,总有效率（ CR ＋PR ）为50.0%。联合组 A 完全缓解（ CR ）5例,部分缓解（ PR ）8例,好转（M R ）5例,稳定（ SD ）2例。总有效率（ CR ＋PR ）为65.0%。三组之间总有效率比较差异有统计学意义（P 0.05）和单纯化疗组（P 〉0.01）。结论 DC-CIK 联合靶向药物和化疗治疗转移性胃肠恶性肿瘤，瘤体变化总有效率和生存质量明显提高。

英文摘要：

Objective To estimate the clinical value of DC-CIK cell immune therapy combined with molecular targeted therapy for metastatic malignant gastrointestinal tumor. Methods 60 cases of gastrointestinal tumor were divided into DC-CIK, targeting plus chemotherapy group （20 cases of group A,）, targeting plus chemotherapy group （group B, 20 cases） and chemotherapy only group （control group, 20 cases）. Venous blood of patients with 50 ml were extracted, and DC-CIK cell were cultured fort14 days later, and the group A were treated with DC-CIK infusion. Changes of before and after tumor treatment were observed, and body weight changes, Karnofsky score, simultaneous recording of survival. to assess the survival quality improvement were evaluated by score and physical volume with K Arno fsky change. Results There was complete remission （CR） in 2 cases, partial remission （PR） in 3 cases,improvement in 8 cases （MR）, stable （SD） in 3 cases, no change （PD） in 4 cases in control group,and the total effective rate（CR ＋ PR） was 25%.There was complete remission （CR） in 2 cases, partial remission （PR） in 3 cases,improvement in 8 cases （MR）, stable （SD） in 3 cases, no change （PD） in 4 cases in control group,and the total effective rate（CR ＋ PR） was 25%. There was complete remission （CR） in 3 cases, partial remission （PR） in 7 cases,improvement in7 cases （MR）, stable （SD） in 23 cases, no change （PD） in 1 cases in the combined group B,and the total effective rate（CR ＋ PR） was 50%.There was complete remission （CR） in 5 cases, partial remission （PR） in 8 cases,improvement in 5 cases （MR）, stable （SD） in 2 cases in combined group A,and the total effective rate（CR ＋ PR） was 65%. Conclusion DC-CIK cell therapy could enhance the effects of anti-cancer, which probably provide a potent immune therapeutic strategy for patients with metastatic malignant gastrointestinal tumor.